A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

PURPOSE: Differentiated thyroid cancer (DTC) responds to VEGF receptor inhibitors. VEGF signals through RAS/RAF/ MEK signaling. We evaluated the safety and efficacy of the VEGF receptor inhibitor pazopanib and MEK inhibitor trametinib in advanced solid tumors and DTC. PATIENTS AND METHODS: Patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Kurzrock, Razelle, Ball, Douglas W., Zahurak, Marianna L., Nelkin, Barry D., Subbiah, Vivek, Ahmed, Shabina, O’Connor, Ashley, Karunsena, Enusha, Parkinson, Rose M., Bishop, Justin A., Ha, Yoonji, Sharma, Rajni, Gocke, Christopher D., Zinner, Ralph, Rudek, Michelle A., Sherman, Steven I., Azad, Nilofer S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038784/
https://ncbi.nlm.nih.gov/pubmed/31186313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1881
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados